Biovista featured in FirstWorld’s latest report, “Drug Combinations: New Rules, New Opportunities”

For years, drug therapy has been built on that basic equation. Yet as genomic biology sheds light on the astonishing intricacy of disease pathology, it is clear that drugs that combine several compounds must be developed in response.


According to Biovista president Dr Aris Persidis, the possibility of such combination drugs “opens up this wonderful world of re-exploration of shelved, ineffective compounds in the pipelines of pharma companies that can be investigated for additive effects.”

Read More…